201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. - Decoster, L.; Aftimos, P.G.; Rottey, S.; Prenen, H.; Collignon, J.J.; Mebis, J.; Canon, J-L.; Fastenaekels, V.; Cappoen, N.; Joris, S.R.; De Grève, J. (Annals of Oncology, 2023)